CINCINNATI--(BUSINESS WIRE)--Jul. 2, 2013-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the MyTaq^TM Extract-PCR Kit.

Powered by the high performance MyTaq^TM DNA Polymerase, the MyTaq^TM Extract-PCR Kit offers a quick and easy alternative for the extraction and amplification of DNA from a variety of mammalian tissue types. Researchers using the MyTaq^TM Extract-PCR Kit can replace complicated and time consuming extraction methods with a simple 15 minute, single tube, protocol; making it perfect for high throughput applications, such as mouse genotyping and sequencing.

Marco Calzavara, President of Bioline commented, "With the MyTaq^TM Extract-PCR Kit; researchers can now quickly achieve the purity and yield necessary for high-performance PCR and real time PCR experiments from solid tissues, such as mouse tail or mouse ear. This makes MyTaq^TM extract the perfect addition to our widely used PCR reagents.”

Richard L. Eberly, President of Meridian Life Science, Inc., stated, “We are delighted to release the MyTaq^TM Extract-PCR Kit, another product in the rapidly expanding portfolio of highly specialized molecular biology reagents from Bioline. We are committed to our life science customers and to bringing innovation and quality products; such as the family of MyTaq™ products to the research laboratory, clinical diagnostic laboratories, and biotechnology companies.”

ABOUT MERIDIAN BIOSCIENCE, INC.

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded on NASDAQ’s Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.

ADDITIONAL INFORMATION
For more information about Bioline, please visit www.bioline.com
For more information about Meridian Life Science, Inc., please visit www.meridianlifescience.com
For more information about Meridian Bioscience, Inc., please visit www.meridianbioscience.com
Richard L. Eberly, rick.eberly@meridianbioscience.com

Source: Meridian Bioscience, Inc.

Meridian Bioscience, Inc.
Richard L. Eberly, 513-271-3700